Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Germany expects AstraZeneca to deliver 3M vaccine doses in February,Reuters says » 15:30
01/24/21
01/24
15:30
01/24/21
15:30
AZN

AstraZeneca

$53.26 /

+0.73 (+1.39%)

Germany expects…

Germany expects AstraZeneca to deliver 3M doses of its COVID-19 vaccine in February despite the company's latest production problems, Health Minister Jens Spahn told Bild am Sonntag newspaper. AstraZeneca informed European Union officials it would cut deliveries of its COVID-19 vaccine to the bloc by 60% to 31M doses in the first quarter of the year due to production problems, a senior official told Reuters. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$53.26 /

+0.73 (+1.39%)

AZN AstraZeneca
$53.26 /

+0.73 (+1.39%)

01/22/21 Barclays
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays
01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
AZN AstraZeneca
$53.26 /

+0.73 (+1.39%)

AZN AstraZeneca
$53.26 /

+0.73 (+1.39%)

AZN AstraZeneca
$53.26 /

+0.73 (+1.39%)

AZN AstraZeneca
$53.26 /

+0.73 (+1.39%)

Friday
Periodicals
J&J director says company could boost vaccine availability by spring, CNBC says » 16:18
01/22/21
01/22
16:18
01/22/21
16:18
JNJ

Johnson & Johnson

$163.68 /

+1.99 (+1.23%)

Johnson & Johnson…

Johnson & Johnson board member Dr. Mark McClellan said that "if the clinical trial works out," the company may be able to significantly boost America's COVID-19 vaccine supply availability within a matter of weeks, CNBC's Emily DeCiccio reports. I do know that J&J is making a very large supply, going all out with its production, both here in the U.S. and elsewhere around the world, with the goal of having perhaps enough vaccines for 100 million Americans by spring, by this April or so," said the former FDA Commissioner in a Thursday evening interview on CNBC. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

01/15/21 B. Riley Securities
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
12/29/20 Piper Sandler
Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

Periodicals
AstraZeneca to slash EU COVID-19 vaccine deliveries by 60% in Q1, Reuters says » 15:25
01/22/21
01/22
15:25
01/22/21
15:25
AZN

AstraZeneca

$53.21 /

+0.68 (+1.29%)

AstraZeneca has informed…

AstraZeneca has informed European Union officials that it would reduce deliveries of its coronavirus vaccine to the bloc by 60% to 31M doses in the first quarter of 2021 due to production issues, Reuters' Francesco Guarascio reports, citing a senior official. The company was forecast to deliver to the 27 EU countries roughly 80M shots by the end of March, the author notes, citing the official who was involved in the talks. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

01/22/21 Barclays
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays
01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

AZN AstraZeneca
$53.21 /

+0.68 (+1.29%)

Recommendations
AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays » 15:00
01/22/21
01/22
15:00
01/22/21
15:00
AZN

AstraZeneca

$53.30 /

+0.77 (+1.47%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis lowered the firm's price target on AstraZeneca to 9,000 GBp from 9,300 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

AZN AstraZeneca
$53.30 /

+0.77 (+1.47%)

Hot Stocks
Pfizer, BioNTech reach agreement with COVAX for advance purchase of vaccine » 12:02
01/22/21
01/22
12:02
01/22/21
12:02
PFE

Pfizer

$36.47 /

-0.02 (-0.05%)

, BNTX

BioNTech

$106.21 /

+0.87 (+0.83%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech (BNTX) announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021. COVAX is a global initiative coordinated by the Global Alliance for Vaccines and Immunization, the Coalition for Epidemic Preparedness Innovations and the World Health Organization, to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels. COVAX includes an Advanced Market Commitment financial mechanism that aims to ensure that 92 low- and lower-middle-income countries will be able to secure access to COVID-19 vaccines at the same time as higher-income countries. The first doses are expected to be delivered in the first quarter of 2021, subject to the negotiation and execution of supply agreements under the COVAX Facility structure. For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price. Financial terms of the agreement were not disclosed.

ShowHide Related Items >><<
PFE Pfizer
$36.47 /

-0.02 (-0.05%)

BNTX BioNTech
$106.21 /

+0.87 (+0.83%)

PFE Pfizer
$36.47 /

-0.02 (-0.05%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
BNTX BioNTech
$106.21 /

+0.87 (+0.83%)

12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
PFE Pfizer
$36.47 /

-0.02 (-0.05%)

BNTX BioNTech
$106.21 /

+0.87 (+0.83%)

  • 23
    Jul
  • 06
    Feb
PFE Pfizer
$36.47 /

-0.02 (-0.05%)

BNTX BioNTech
$106.21 /

+0.87 (+0.83%)

PFE Pfizer
$36.47 /

-0.02 (-0.05%)

BNTX BioNTech
$106.21 /

+0.87 (+0.83%)

PFE Pfizer
$36.47 /

-0.02 (-0.05%)

BNTX BioNTech
$106.21 /

+0.87 (+0.83%)

Periodicals
EU to see delay of AstraZeneca COVID vaccine delivery, FT reports » 11:53
01/22/21
01/22
11:53
01/22/21
11:53
AZN

AstraZeneca

$53.07 /

+0.54 (+1.03%)

The European Union will…

The European Union will experience a delay in the delivery of COVID-19 vaccines made by AstraZeneca in partnership with Oxford, the Financial Times reports. The company said that initial volumes of the vaccine will be "lower than originally anticipated," the report says. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

AZN AstraZeneca
$53.07 /

+0.54 (+1.03%)

Periodicals
AstraZeneca informs EU Commission of vaccine delivery issues, Bild says » 10:38
01/22/21
01/22
10:38
01/22/21
10:38
AZN

AstraZeneca

$53.02 /

+0.49 (+0.93%)

A translation of a…

A translation of a German-language report from Bild indicates that AstraZeneca has informed the EU Commission that it will initially be able to deliver significantly less of the Oxford vaccine for COVID-19 after approval than had been anticipated. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

AZN AstraZeneca
$53.02 /

+0.49 (+0.93%)

Hot Stocks
Coty promotes Stephane Delbos to chief procurement officer » 08:20
01/22/21
01/22
08:20
01/22/21
08:20
COTY

Coty

$6.88 /

-0.01 (-0.15%)

, PFE

Pfizer

$36.49 /

+0.01 (+0.03%)

Coty (COTY) announced the…

Coty (COTY) announced the promotion of Stephane Delbos to chief procurement officer, or CPO, effective February 1. Delbos, who joined Coty in 2010 as global sourcing director, has been promoted from his current role as senior VP for transformation, indirect and procurement operations, where he has played an important role in driving forward Coty's broader transformation agenda. Delbos will join Coty's senior leadership team and report to Gordon von Bretten, chief transformation officer. Delbos is a senior procurement professional with over 18 years' experience in the beauty and pharmaceutical industries. Prior to joining Coty, he held several local and global procurement positions at Pfizer (PFE). In his new role, Delbos will be responsible for implementing Coty's multi-year procurement strategy, which includes achieving a significant cost reduction target by FY23, reducing complexity and strengthening Coty's new product pipeline. This forms an important element of Coty's transformation program, announced in 2020.

ShowHide Related Items >><<
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

COTY Coty
$6.88 /

-0.01 (-0.15%)

COTY Coty
$6.88 /

-0.01 (-0.15%)

12/07/20 Wells Fargo
Coty downgraded to Underweight from Equal Weight at Wells Fargo
11/19/20
Fly Intel: Top five analyst upgrades
11/19/20 Citi
Coty upgraded to Buy from Neutral at Citi
11/09/20 Deutsche Bank
Coty price target raised to $6 from $4 at Deutsche Bank
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

COTY Coty
$6.88 /

-0.01 (-0.15%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

COTY Coty
$6.88 /

-0.01 (-0.15%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

COTY Coty
$6.88 /

-0.01 (-0.15%)

Thursday
Hot Stocks
ViiV Healthcare announces FDA approval of Cabenuva » 16:46
01/21/21
01/21
16:46
01/21/21
16:46
GSK

GlaxoSmithKline

$37.79 /

-0.23 (-0.60%)

, PFE

Pfizer

$36.49 /

+0.01 (+0.03%)

, JNJ

Johnson & Johnson

$161.69 /

-0.71 (-0.44%)

ViiV Healthcare, the…

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced that the U.S. FDA approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines, ViiV Healthcare's cabotegravir and Janssen's (JNJ) rilpivirine, dosed once monthly, as an option to replace the current antiretroviral regimen in those who are virologically suppressed on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.

ShowHide Related Items >><<
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

01/20/21 UBS
GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS
01/20/21
Fly Intel: Top five analyst downgrades
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

01/15/21 B. Riley Securities
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
12/29/20 Piper Sandler
Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

Periodicals
Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports » 15:21
01/21/21
01/21
15:21
01/21/21
15:21
PFE

Pfizer

$36.45 /

-0.035 (-0.10%)

, BNTX

BioNTech

$107.01 /

+3.71 (+3.59%)

Pfizer (PFE) has cut in…

Pfizer (PFE) has cut in half the volume of COVID-19 vaccines it will deliver to some EU countries this week, Reuters' Radu-Sorin Marinas, Jan Lopatka, and Tsvetelia Tsolova report, citing government officials. Pfizer and its partner BioNTech (BNTX) have declined to comment on the cuts beyond their statement last week, the report noted. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$36.45 /

-0.035 (-0.10%)

BNTX BioNTech
$107.01 /

+3.71 (+3.59%)

PFE Pfizer
$36.45 /

-0.035 (-0.10%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
BNTX BioNTech
$107.01 /

+3.71 (+3.59%)

12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
PFE Pfizer
$36.45 /

-0.035 (-0.10%)

BNTX BioNTech
$107.01 /

+3.71 (+3.59%)

  • 23
    Jul
  • 06
    Feb
PFE Pfizer
$36.45 /

-0.035 (-0.10%)

BNTX BioNTech
$107.01 /

+3.71 (+3.59%)

PFE Pfizer
$36.45 /

-0.035 (-0.10%)

BNTX BioNTech
$107.01 /

+3.71 (+3.59%)

PFE Pfizer
$36.45 /

-0.035 (-0.10%)

BNTX BioNTech
$107.01 /

+3.71 (+3.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.